Cliniq s.r.o. — Clinical Trial Site

46 Registered trials

15 Currently recruiting

Organisation

Cliniq s.r.o.

Location

Bratislava, Slovakia

Identifier

ORG-100043638

Address

Bezrucova 5, Stare Mesto, 811 09, Slovakia

Departments

3353: Dermatovenerologická ambulancia
Ambulancia pediatrickej gastroenterologie, hepatologie a vyzivy 1
Cardiology
Centrum gastroenterológie
Cliniq s. r. o.
Dematovenerological centre
Dermatovenerology
Gastroenterológia
Gastroenterologicka ambulancia
Gastroenterologicke centrum
Gastroenterologické centrum Bezručova Junior
Gastroenterology
Gastroenterology Department
Gastroenterology outpatient clinic
Kardiologicka ambulancia
n/a
NA
Outpatient Cardiology Care
Poliklinika Bezrucova (Cliniq s.r.o.)
Rheumatology
SK10004: Gastroenterologicka ambulancia
SK10005: Gastroenterologicka ambulancia

Clinical trials at this site (46)

Search interface

Study to Evaluate Plozasiran in Adults with Severe Hypertriglyceridemia (SHASTA 3 Study) Ended

2023-509300-14-00 Severe hypertriglyceridemia (SHTG) 5 2024-10-31
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Ended

2023-508636-61-00 Crohn’s Disease 5 2024-10-24
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in … Ended

2023-506769-67-00 Moderate to Severely Active Ulcerative Colitis 4 2024-09-04
A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended

2023-509190-23-00 Atherosclerotic Cardiovascular Disease Elevated lp(a) 5 2024-09-03
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES) Ended

2023-508630-34-00 Overweight 5 2024-05-28
A Phase 3 Placebo-Controlled Study With Randomized Dose Up/Dose Down Extension Period Investigating the Efficacy, Safety, and Tolerability o… Ended

2022-502518-98-00 nonsegmental vitiligo 5 2024-04-26
Randomized, Double-Blind, Placebo-Controlled, Multiple-Attack Study with an Open-Label Extension to Evaluate the Efficacy, Safety, Tolerabil… Ended

2023-506029-12-00 Migraine 5 2024-04-03
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn’s Disease Ended

2024-515027-11-00 Crohn’s disease 4 2023-06-29
A Phase 2b Study to Evaluate MORF-057 in Adults with Moderately to Severely Active UC Ended

2022-500953-17-00 Moderately to severely active ulcerative colitis 4 2023-03-23
A Phase 3 Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely… Ended

2023-504719-34-00 Moderate to Severly Active Ulcerative Colitis 5 2023-02-21
Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colit… Ended

2023-504743-13-00 Moderately to Severely Active Ulcerative Colitis 4 2022-11-30
Effects of ABX464 during long-term treatment in patients with moderate to severe ulcerative colitis Ended

2023-507974-42-00 Moderate to Severe Ulcerative Colitis 4 2021-12-01
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn’s Disease (VIVID-2) Ended

2022-502841-91-00 Crohn’s Disease 5 2020-08-12
A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis Ended

2023-504718-31-00 Moderately to Severely Active Ulcerative Colitis 10 2019-10-19
LUCENT-3 Extension Study of Mirikizumab in Ulcerative Colitis Ended

2023-507657-15-00 Ulcerative Colitis 5 2018-09-13
A study to compare the effect of AVT16 and Entyvio® in subjects with moderate to severe active ulcerative colitis. Ended

2023-507705-34-00 Moderate to Severe Active Ulcerative Colitis 5 2025-08-29
A Study to Investigate Bowel Urgency in Adults with Moderately to Severely Active Ulcerative Colitis Treated with Mirikizumab Ended

2022-502393-16-00 Moderately to Severely Active Ulcerative Colitis 5 2023-09-06
An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis Ended

2022-502994-40-00 Rheumatoid Arthritis 4 2023-09-04
ABTECT-2 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -2 Ended

2022-500536-11-01 Moderately to severely active ulcerative colitis 5 2023-06-08
This is a study to evaluate dose-flexibility of Upadacitinib in Adult Subjects with Moderate to Severe Atopic Dermatitis Ended

2023-504869-23-00 Dermatitis atopic 11 2023-05-31
Clinical Outcomes, Tolerability and Safety of Oral Pantoprazole in Pediatric Participants Ended

2023-508770-28-00 EROSIVE ESOPHAGITIS 4 2021-10-05
Multicenter Study of Oral Ozanimod as Maintenance Therapy in patients with Moderately to Severely Active Crohn's Disease Ended

2023-510426-33-00 Moderately to Severely Active Crohn's Disease 5 2018-09-27